vs
雅培（ABT）与Cooper Companies (The)（COO）财务数据对比。点击上方公司名可切换其他公司
雅培的季度营收约是Cooper Companies (The)的10.8倍（$11.5B vs $1.1B）。雅培净利率更高（15.5% vs 7.9%，领先7.6%）。Cooper Companies (The)同比增速更快（4.6% vs 4.4%）。雅培自由现金流更多（$2.6B vs $149.9M）。过去两年雅培的营收复合增速更高（7.2% vs 6.9%）
雅培是总部位于美国伊利诺伊州雅培园的跨国医疗健康企业，业务覆盖美国境外市场药品销售、诊断产品、营养产品及医疗器械等板块，在全球医疗健康领域拥有较高的行业知名度与广泛的市场覆盖。
CooperCompanies是总部位于美国加利福尼亚州圣拉蒙的全球医疗设备企业，旗下设有两大业务单元：主营隐形眼镜生产的库博光学，以及面向女性健康市场提供医疗设备、生育及基因组相关产品的库博外科。
ABT vs COO — 直观对比
营收规模更大
ABT
是对方的10.8倍
$1.1B
营收增速更快
COO
高出0.2%
4.4%
净利率更高
ABT
高出7.6%
7.9%
自由现金流更多
ABT
多$2.5B
$149.9M
两年增速更快
ABT
近两年复合增速
6.9%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $11.5B | $1.1B |
| 净利润 | $1.8B | $84.6M |
| 毛利率 | 57.0% | 61.1% |
| 营业利润率 | 19.6% | 13.2% |
| 净利率 | 15.5% | 7.9% |
| 营收同比 | 4.4% | 4.6% |
| 净利润同比 | -80.8% | -28.0% |
| 每股收益（稀释后） | $1.01 | $0.42 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ABTCOO
| Q4 25 | $11.5B | $1.1B | ||
| Q3 25 | $11.4B | $1.1B | ||
| Q2 25 | $11.1B | $1.0B | ||
| Q1 25 | $10.4B | $964.7M | ||
| Q4 24 | $11.0B | $1.0B | ||
| Q3 24 | $10.6B | $1.0B | ||
| Q2 24 | $10.4B | $942.6M | ||
| Q1 24 | $10.0B | $931.6M |
净利润ABTCOO
| Q4 25 | $1.8B | $84.6M | ||
| Q3 25 | $1.6B | $98.3M | ||
| Q2 25 | $1.8B | $87.7M | ||
| Q1 25 | $1.3B | $104.3M | ||
| Q4 24 | $9.2B | $117.5M | ||
| Q3 24 | $1.6B | $104.7M | ||
| Q2 24 | $1.3B | $88.9M | ||
| Q1 24 | $1.2B | $81.2M |
毛利率ABTCOO
| Q4 25 | 57.0% | 61.1% | ||
| Q3 25 | 55.4% | 65.3% | ||
| Q2 25 | 56.4% | 67.8% | ||
| Q1 25 | 56.9% | 68.4% | ||
| Q4 24 | 55.0% | 66.5% | ||
| Q3 24 | 55.8% | 66.1% | ||
| Q2 24 | 55.6% | 67.0% | ||
| Q1 24 | 55.2% | 67.0% |
营业利润率ABTCOO
| Q4 25 | 19.6% | 13.2% | ||
| Q3 25 | 18.1% | 16.6% | ||
| Q2 25 | 18.4% | 18.4% | ||
| Q1 25 | 16.3% | 18.9% | ||
| Q4 24 | 17.4% | 19.5% | ||
| Q3 24 | 17.5% | 19.2% | ||
| Q2 24 | 16.1% | 17.2% | ||
| Q1 24 | 13.9% | 16.4% |
净利率ABTCOO
| Q4 25 | 15.5% | 7.9% | ||
| Q3 25 | 14.5% | 9.3% | ||
| Q2 25 | 16.0% | 8.7% | ||
| Q1 25 | 12.8% | 10.8% | ||
| Q4 24 | 84.1% | 11.5% | ||
| Q3 24 | 15.5% | 10.4% | ||
| Q2 24 | 12.5% | 9.4% | ||
| Q1 24 | 12.3% | 8.7% |
每股收益（稀释后）ABTCOO
| Q4 25 | $1.01 | $0.42 | ||
| Q3 25 | $0.94 | $0.49 | ||
| Q2 25 | $1.01 | $0.44 | ||
| Q1 25 | $0.76 | $0.52 | ||
| Q4 24 | $5.26 | $0.59 | ||
| Q3 24 | $0.94 | $0.52 | ||
| Q2 24 | $0.74 | $0.44 | ||
| Q1 24 | $0.70 | $0.41 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $8.9B | $110.6M |
| 总债务越低越好 | $12.9B | $2.5B |
| 股东权益账面价值 | $52.1B | $8.2B |
| 总资产 | $86.7B | $12.4B |
| 负债/权益比越低杠杆越低 | 0.25× | 0.30× |
8季度趋势，按日历期对齐
现金及短期投资ABTCOO
| Q4 25 | $8.9B | $110.6M | ||
| Q3 25 | $7.7B | $124.9M | ||
| Q2 25 | $7.3B | $116.2M | ||
| Q1 25 | $6.8B | $100.9M | ||
| Q4 24 | $8.0B | $107.6M | ||
| Q3 24 | $7.8B | $109.7M | ||
| Q2 24 | $7.2B | $112.4M | ||
| Q1 24 | $6.7B | $135.2M |
总债务ABTCOO
| Q4 25 | $12.9B | $2.5B | ||
| Q3 25 | — | $2.4B | ||
| Q2 25 | — | $2.5B | ||
| Q1 25 | — | $2.5B | ||
| Q4 24 | $14.1B | $2.6B | ||
| Q3 24 | — | $2.6B | ||
| Q2 24 | — | $2.7B | ||
| Q1 24 | — | $2.7B |
股东权益ABTCOO
| Q4 25 | $52.1B | $8.2B | ||
| Q3 25 | $51.0B | $8.4B | ||
| Q2 25 | $50.6B | $8.3B | ||
| Q1 25 | $48.8B | $8.1B | ||
| Q4 24 | $47.7B | $8.1B | ||
| Q3 24 | $39.8B | $7.9B | ||
| Q2 24 | $39.3B | $7.8B | ||
| Q1 24 | $38.8B | $7.7B |
总资产ABTCOO
| Q4 25 | $86.7B | $12.4B | ||
| Q3 25 | $84.2B | $12.4B | ||
| Q2 25 | $84.0B | $12.4B | ||
| Q1 25 | $81.4B | $12.2B | ||
| Q4 24 | $81.4B | $12.3B | ||
| Q3 24 | $74.4B | $12.1B | ||
| Q2 24 | $73.0B | $12.0B | ||
| Q1 24 | $72.5B | $12.0B |
负债/权益比ABTCOO
| Q4 25 | 0.25× | 0.30× | ||
| Q3 25 | — | 0.29× | ||
| Q2 25 | — | 0.30× | ||
| Q1 25 | — | 0.31× | ||
| Q4 24 | 0.30× | 0.32× | ||
| Q3 24 | — | 0.33× | ||
| Q2 24 | — | 0.34× | ||
| Q1 24 | — | 0.35× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $3.3B | $247.9M |
| 自由现金流经营现金流 - 资本支出 | $2.6B | $149.9M |
| 自由现金流率自由现金流/营收 | 22.9% | 14.1% |
| 资本支出强度资本支出/营收 | 6.0% | 9.2% |
| 现金转化率经营现金流/净利润 | 1.87× | 2.93× |
| 过去12个月自由现金流最近4个季度 | $7.4B | $433.7M |
8季度趋势，按日历期对齐
经营现金流ABTCOO
| Q4 25 | $3.3B | $247.9M | ||
| Q3 25 | $2.8B | $261.4M | ||
| Q2 25 | $2.0B | $96.2M | ||
| Q1 25 | $1.4B | $190.6M | ||
| Q4 24 | $2.9B | $268.1M | ||
| Q3 24 | $2.7B | $207.5M | ||
| Q2 24 | $2.0B | $111.0M | ||
| Q1 24 | $1.0B | $122.7M |
自由现金流ABTCOO
| Q4 25 | $2.6B | $149.9M | ||
| Q3 25 | $2.3B | $164.5M | ||
| Q2 25 | $1.5B | $18.1M | ||
| Q1 25 | $933.0M | $101.2M | ||
| Q4 24 | $2.1B | $128.1M | ||
| Q3 24 | $2.1B | $118.5M | ||
| Q2 24 | $1.4B | $36.9M | ||
| Q1 24 | $627.0M | $4.6M |
自由现金流率ABTCOO
| Q4 25 | 22.9% | 14.1% | ||
| Q3 25 | 20.2% | 15.5% | ||
| Q2 25 | 13.9% | 1.8% | ||
| Q1 25 | 9.0% | 10.5% | ||
| Q4 24 | 19.6% | 12.6% | ||
| Q3 24 | 20.2% | 11.8% | ||
| Q2 24 | 13.8% | 3.9% | ||
| Q1 24 | 6.3% | 0.5% |
资本支出强度ABTCOO
| Q4 25 | 6.0% | 9.2% | ||
| Q3 25 | 4.4% | 9.1% | ||
| Q2 25 | 4.5% | 7.8% | ||
| Q1 25 | 4.7% | 9.3% | ||
| Q4 24 | 6.6% | 13.7% | ||
| Q3 24 | 5.2% | 8.9% | ||
| Q2 24 | 5.1% | 7.9% | ||
| Q1 24 | 4.0% | 12.7% |
现金转化率ABTCOO
| Q4 25 | 1.87× | 2.93× | ||
| Q3 25 | 1.70× | 2.66× | ||
| Q2 25 | 1.15× | 1.10× | ||
| Q1 25 | 1.07× | 1.83× | ||
| Q4 24 | 0.31× | 2.28× | ||
| Q3 24 | 1.64× | 1.98× | ||
| Q2 24 | 1.51× | 1.25× | ||
| Q1 24 | 0.84× | 1.51× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ABT
暂无分部数据
COO
| Sphere Other | $365.0M | 34% |
| Toric And Multifocal | $344.7M | 32% |
| Office And Surgical | $214.5M | 20% |
| Fertility | $140.9M | 13% |
